FDA Approves Gloucester Pharmaceuticals' ISTODAX For Patients With Cutaneous T-cell Lymphoma

Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX(R) (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.